--- title: "ProPhase Labs Secures Flexible $10 Million Equity Facility" type: "News" locale: "en" url: "https://longbridge.com/en/news/273564732.md" description: "ProPhase Labs, Inc. has secured a flexible $10 million equity facility through a Stock Purchase Agreement with Generating Alpha Ltd. The agreement allows ProPhase to issue shares at its discretion, providing non-obligatory funding to strengthen its balance sheet. The latest analyst rating for PRPH stock is a Hold with a price target of $0.13. Spark's AI Analyst rates PRPH as Neutral, citing weak financial performance and bearish technicals, but notes potential catalysts and risks associated with corporate actions." datetime: "2026-01-23T22:55:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273564732.md) - [en](https://longbridge.com/en/news/273564732.md) - [zh-HK](https://longbridge.com/zh-HK/news/273564732.md) --- # ProPhase Labs Secures Flexible $10 Million Equity Facility ### Claim 50% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Prophase Labs ( (PRPH) ) has provided an announcement. On January 16, 2026, ProPhase Labs, Inc. entered into a Stock Purchase Agreement with Generating Alpha Ltd., securing access to up to $10 million in equity capital through an at‑the‑company’s‑discretion equity line facility. Under the deal, ProPhase granted the investor 549,105 shares of common stock and a prefunded warrant for up to 240,369 additional shares as a commitment fee, with any further share issuance occurring only at the company’s election, providing flexible, non-obligatory funding that may strengthen its balance sheet and financial optionality without imposing mandatory capital raises on existing stakeholders. The most recent analyst rating on (PRPH) stock is a Hold with a $0.13 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page. **Spark’s Take on PRPH Stock** According to Spark, TipRanks’ AI Analyst, PRPH is a Neutral. Overall score reflects weak financial performance (sharp revenue decline, negative margins, and negative cash flows) and strongly bearish technicals (well below moving averages with negative MACD). Offsetting factors are limited to mixed but potentially impactful earnings-call catalysts (collections and product partnering) and corporate actions that include both upside (strategic transaction potential) and significant risks (delisting/OTC and dilution-related volatility). To see Spark’s full report on PRPH stock, click here. **More about Prophase Labs** **Average Trading Volume:** 1,169,804 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** $879.2K For a thorough assessment of PRPH stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [IHF.US](https://longbridge.com/en/quote/IHF.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md) - [PRPH.US](https://longbridge.com/en/quote/PRPH.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) ## Related News & Research - [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md) - [Biotech experts want FDA drug reviews based on science, not politics](https://longbridge.com/en/news/293453841.md) - [Generic drug sector seeks policy fixes after Trump tariff threat](https://longbridge.com/en/news/293501714.md) - [Trump Says US To Exempt Import Tariff On Generic Drugs For Two Years](https://longbridge.com/en/news/293481843.md) - [Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US](https://longbridge.com/en/news/293415324.md)